[{"begin": 209, "end": 247, "text": "open-label phase 1b/2 randomised study", "tokenized_text": "open - label phase 1b / 2 randomised study", "type": "title", "id": 0}, {"begin": 249, "end": 264, "text": "Lancet Haematol", "tokenized_text": "Lancet Haematol", "type": "venue", "id": 1}, {"begin": 266, "end": 270, "text": "2015", "tokenized_text": "2015", "type": "year", "id": 2}, {"begin": 0, "end": 126, "text": "Cheah CY, Belada D, Fanale MA, Janikova A, Czucman MS, Flinn IW, Kapp AV, Ashkenazi A, Kelley S, Bray GL, Holden S, Seymour JF", "tokenized_text": "Cheah CY , Belada D , Fanale MA , Janikova A , Czucman MS , Flinn IW , Kapp AV , Ashkenazi A , Kelley S , Bray GL , Holden S , Seymour JF", "type": "authors", "id": 3}, {"begin": 128, "end": 208, "text": "Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an", "tokenized_text": "Dulanermin with rituximab in patients with relapsed indolent B - cell lymphoma : an", "type": "title", "id": 4}]